scispace - formally typeset
Open AccessJournal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
- Vol. 397, Iss: 10277, pp 881-891
TLDR
The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
About
This article is published in The Lancet.The article was published on 2021-03-06 and is currently open access. It has received 862 citations till now. The article focuses on the topics: Booster dose & Vaccine efficacy.

read more

Citations
More filters
References
More filters
Journal ArticleDOI

Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines.

TL;DR: This model suggests that boost doses and timings should be selected according to the T cell response elicited by priming, and boosting during late stages of clonal contraction would maximize T cell memory production for vaccines using lower doses of irradiated sporozoites.
Posted ContentDOI

Modelling Decay of Population Immunity With Proposed Second Dose Deferral Strategy

Jurgens Graham
- 06 Jan 2021 - 
TL;DR: A model to project population immunity between the two strategies shows that if there is an increased decay rate of one dose efficacy relative to two dose decay rates, it is highly unlikely to nullify the benefit of increased population immunity seen in a second dose deferral strategy.
Related Papers (5)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 -